Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRG NASDAQ:BFRI NASDAQ:CVKD NASDAQ:PPCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$0.62-1.6%$0.81$0.43▼$2.04$11.65M-2.89312,832 shs379,767 shsBFRIBiofrontera$0.87-2.4%$0.98$0.55▼$1.19$11.35M0.83196,978 shs162,709 shsCVKDCadrenal Therapeutics$3.70-8.2%$5.06$3.70▼$14.69$11.56M1.5963,238 shs111,106 shsPPCBPropanc Biopharma$2.27-6.6%$2.26$1.30▼$270.25$5.54M3.488.79 million shs1.85 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI-7.29%-18.40%+1.21%+5.39%-66.05%BFRIBiofrontera+2.70%-10.92%-12.25%+1.92%+36.69%CVKDCadrenal Therapeutics-2.66%-6.50%-22.35%-45.54%-73.13%PPCBPropanc Biopharma+80.00%+46.39%+7.40%-23.58%-98.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$0.62-1.6%$0.81$0.43▼$2.04$11.65M-2.89312,832 shs379,767 shsBFRIBiofrontera$0.87-2.4%$0.98$0.55▼$1.19$11.35M0.83196,978 shs162,709 shsCVKDCadrenal Therapeutics$3.70-8.2%$5.06$3.70▼$14.69$11.56M1.5963,238 shs111,106 shsPPCBPropanc Biopharma$2.27-6.6%$2.26$1.30▼$270.25$5.54M3.488.79 million shs1.85 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI-7.29%-18.40%+1.21%+5.39%-66.05%BFRIBiofrontera+2.70%-10.92%-12.25%+1.92%+36.69%CVKDCadrenal Therapeutics-2.66%-6.50%-22.35%-45.54%-73.13%PPCBPropanc Biopharma+80.00%+46.39%+7.40%-23.58%-98.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 1.00SellN/AN/ABFRIBiofrontera 2.00HoldN/AN/ACVKDCadrenal Therapeutics 2.00Hold$13.00251.35% UpsidePPCBPropanc Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PPCB, BFRG, CVKD, and BFRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026PPCBPropanc Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026BFRGBullfrog AI Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$120K95.48N/AN/A$0.19 per share3.25BFRIBiofrontera$41.71M0.27N/AN/A$0.90 per share0.96CVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/APPCBPropanc BiopharmaN/AN/AN/AN/A$29.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$6.50M-$0.54N/AN/AN/AN/A-217.80%-174.57%N/ABFRIBiofrontera-$10.54M-$0.97N/A14.42N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)CVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%8/10/2026 (Estimated)PPCBPropanc Biopharma-$58.92M-$24.25N/AN/AN/AN/A-151.28%-109.53%N/ALatest PPCB, BFRG, CVKD, and BFRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026BFRGBullfrog AIN/A-$0.12N/A-$0.12N/AN/A5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/A3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/19/2026Q4 2025BFRGBullfrog AIN/A-$0.12N/A-$0.12N/AN/A3/19/2026Q4 2025BFRIBiofrontera$0.29$0.50+$0.21$0.47$16.15 million$17.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A8.158.15BFRIBiofrontera0.781.201.09CVKDCadrenal TherapeuticsN/A2.682.68PPCBPropanc BiopharmaN/A2.372.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%BFRIBiofrontera10.08%CVKDCadrenal Therapeutics7.92%PPCBPropanc BiopharmaN/AInsider OwnershipCompanyInsider OwnershipBFRGBullfrog AI25.16%BFRIBiofrontera4.80%CVKDCadrenal Therapeutics26.09%PPCBPropanc Biopharma28.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI418.54 million13.88 millionNot OptionableBFRIBiofrontera7012.80 million12.19 millionNo DataCVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionablePPCBPropanc Biopharma12.28 million1.63 millionNot OptionablePPCB, BFRG, CVKD, and BFRI HeadlinesRecent News About These CompaniesPropanc Biopharma Authorizes $5.0 Million Share Repurchase ProgramJune 11 at 8:30 AM | globenewswire.comPropanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an ...June 2, 2026 | caledonianrecord.comCPropanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, SpainJune 2, 2026 | markets.businessinsider.comPropanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, SpainJune 2, 2026 | globenewswire.comPropanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next DecadeMay 20, 2026 | markets.businessinsider.comPropanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next DecadeMay 20, 2026 | globenewswire.comPropanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer PatientsMay 19, 2026 | globenewswire.comPropanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate DevelopmentsMay 15, 2026 | quiverquant.comQPropanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 ResultsMay 15, 2026 | globenewswire.comPropanc Biopharma, Inc. Announces 1-for-25 Reverse Stock Split to Enhance Nasdaq ComplianceMay 13, 2026 | quiverquant.comQPropanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth PlansMay 13, 2026 | globenewswire.comPropanc Biopharma Inc.April 24, 2026 | barrons.comRosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCBApril 17, 2026 | businesswire.comRosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation - PPCBApril 16, 2026 | tmcnet.comRosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCBApril 16, 2026 | businesswire.comPropanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, SpainMarch 24, 2026 | globenewswire.comPropanc Biopharma, Inc.: Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme TherapyMarch 12, 2026 | finanznachrichten.dePropanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in ...March 12, 2026 | bakersfield.comBPropanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme TherapyMarch 12, 2026 | globenewswire.comPropanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human StudyMarch 10, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPCB, BFRG, CVKD, and BFRI Company DescriptionsBullfrog AI NASDAQ:BFRG$0.62 -0.01 (-1.61%) Closing price 04:00 PM EasternExtended Trading$0.60 -0.01 (-2.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Biofrontera NASDAQ:BFRI$0.87 -0.02 (-2.39%) Closing price 04:00 PM EasternExtended Trading$0.87 +0.01 (+0.68%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Cadrenal Therapeutics NASDAQ:CVKD$3.70 -0.33 (-8.19%) Closing price 04:00 PM EasternExtended Trading$3.74 +0.04 (+1.08%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Propanc Biopharma NASDAQ:PPCB$2.27 -0.16 (-6.58%) Closing price 04:00 PM EasternExtended Trading$2.07 -0.20 (-8.81%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
